- A phase 1b/2a trial evaluated
once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese
subjects with obesity/overweight
- Pre-clinical studies evaluated the molecular and
pharmacological properties of GZR4, an investigational once-weekly
insulin analog
- Pre-clinical studies evaluated and characterized an
ultra-long-acting basal insulin, GZR33, and its premixed
formulation GZR101
BRIDGEWATER, N.J., June 17,
2024 /CNW/ -- Gan & Lee Pharmaceuticals (Shanghai
Stock Exchange: 603087) announced today the presentation of three
abstracts featuring their investigational products at the American
Diabetes Association's (ADA's[1]) 84th Scientific
Sessions. The meeting will be held in-person and virtually from
June 21-24, 2024, in Orlando, Florida .
All abstracts will be published on the journal
Diabetes® website. Data from the selected studies
will be presented live on June 22,
from 12:30-1:30 PM EDT in the Poster
Hall.
The above abstracts and presentations represent the data that
will be showcased or published by Gan & Lee. This press release
includes forward-looking statements regarding investigational
products currently in development by Gan & Lee. It is important
to note that there are risks associated with drug development, and
there is no guarantee that future studies will produce results
consistent with those presented at the ADA's 84th Scientific
Sessions.
References:
[1]. ADA's 84th
Scientific Sessions.
https://professional.diabetes.org/scientific-sessions
[2]. Zhang M, Zhang Y,
Peng X, et al. GZR18, a novel long-acting GLP-1 analog,
demonstrated positive in vitro and in vivo pharmacokinetic and
pharmacodynamic characteristics in animal models. Eur J Pharmacol.
2022;928:175107. doi:10.1016/j.ejphar.2022.175107
About Gan & Lee
Gan & Lee Pharmaceuticals developed the first Chinese
domestic insulin analog. Currently, Gan & Lee has six core
insulin products, including five insulin analog varieties:
long-acting glargine injection (Basalin®), fast-acting
lispro injection (Prandilin™), fast-acting aspart
injection (Rapilin®), mixed protamine zinc lispro
injection (25R) (Prandilin™25), aspart 30 injection
(Rapilin®30), and one human insulin injection - mixed
protamine human insulin injection (30R)
(Similin®30). The company has two approved
medical devices in China,
namely reusable insulin injection
pen (GanleePen), and disposable pen needle
(GanleeFine®).
In China's second Volume Based Procurement
(VBP) in 2024, Gan & Lee Pharmaceuticals ranked second
overall and first among domestic companies in terms of procurement
demand for insulin analogs. The company is also making strides in
international markets, with the disposable pen needle (GanleeFine®) approved by the US
Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European
Medicines Agency (EMA) in 2024. These achievements
significantly boost Gan & Lee's competitiveness in both
international and domestic markets.
In the future, Gan & Lee will strive for comprehensive
coverage in diabetes treatment. Moving forward with its mission to
become a world-class pharmaceutical company, Gan & Lee will
also actively develop new chemical entities and biological drugs,
focusing on treatments for metabolic diseases, cardiovascular
diseases, and other therapeutic areas.
Further Information
BPRD@ganlee.com（Media）
BD@ganlee.com（Business Development）
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gan--lee-pharmaceuticals-to-present-groundbreaking-data-on-three-innovative-products-at-the-american-diabetes-associations-84th-scientific-sessions-302174901.html
SOURCE Gan & Lee Pharmaceuticals